← Leaderboards
Nicholas J Van Wagoner
University Of Alabama At Birmingham
$3,602,214
Attributed
$3,894,857
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $847.7K · FY2012–23$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,894,857 · 3
By mechanism
U19$2,787,913 · 1
K23$667,980 · 1
R21$438,964 · 1
Top collaborators
- Christina A Muzny2 shared
- Christopher Michael Taylor2 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Jane R. Schwebke$12,395,911
- Robert L Goldenberg$16,578,724
- Christina A Muzny$5,578,242
- William M Geisler$14,663,241
- Christopher Michael Taylor$3,588,060
Others in their field
Top investigators on “Participant”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$407,724,307
- Lawrence Corey · Fred Hutchinson Cancer Center$333,313,234
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Albert Lazzarini · California Institute Of Technology$300,431,866
Research focus
ParticipantResearch DesignBaseClinical ResearchDiagnosisPreventionPatient CareTrainingDesignSex BehaviorSample CollectionSamplingSerumArchivesSexually Transmitted DiseasesPersonsMalePharmaceutical PreparationsBehavioralBacterial VaginosisDiariesFuturePreventSpecimen
Grant awards (12)
The Impact of Testosterone Use on the Vaginal Microbiota in Transgender Men, including Susceptibility to Bacterial Vaginosis$283,494
R21 · FY2023 · AI
The Impact of Testosterone Use on the Vaginal Microbiota in Transgender Men, including Susceptibility to Bacterial Vaginosis$155,470
R21 · FY2022 · AI
DiSCIS Clinical Core$847,662
U19 · FY2018 · AI · contact PI
DiSCIS Clinical Core$602,903
U19 · FY2017 · AI · contact PI
DiSCIS Clinical Core$464,236
U19 · FY2016 · AI · contact PI
Inhibition of Herpes Simplex Virus Type 2 by Tenofovir$133,596
K23 · FY2016 · AI · contact PI
DiSCIS Clinical Core$470,996
U19 · FY2015 · AI · contact PI
Inhibition of Herpes Simplex Virus Type 2 by Tenofovir$133,596
K23 · FY2015 · AI · contact PI
DiSCIS Clinical Core$402,116
U19 · FY2014 · AI · contact PI
Inhibition of Herpes Simplex Virus Type 2 by Tenofovir$133,596
K23 · FY2014 · AI · contact PI
Inhibition of Herpes Simplex Virus Type 2 by Tenofovir$133,596
K23 · FY2013 · AI · contact PI
Inhibition of Herpes Simplex Virus Type 2 by Tenofovir$133,596
K23 · FY2012 · AI · contact PI